vs
Amphastar Pharmaceuticals, Inc.（AMPH）与AdvanSix Inc.（ASIX）财务数据对比。点击上方公司名可切换其他公司
AdvanSix Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的2.0倍（$359.9M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs -0.8%，领先14.1%），AdvanSix Inc.同比增速更快（9.4% vs -1.8%），AdvanSix Inc.自由现金流更多（$36.1M vs $24.6M），过去两年AdvanSix Inc.的营收复合增速更高（3.4% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
AMPH vs ASIX — 直观对比
营收规模更大
ASIX
是对方的2.0倍
$183.1M
营收增速更快
ASIX
高出11.2%
-1.8%
净利率更高
AMPH
高出14.1%
-0.8%
自由现金流更多
ASIX
多$11.5M
$24.6M
两年增速更快
ASIX
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $359.9M |
| 净利润 | $24.4M | $-2.8M |
| 毛利率 | 46.8% | 7.6% |
| 营业利润率 | 19.4% | -0.7% |
| 净利率 | 13.3% | -0.8% |
| 营收同比 | -1.8% | 9.4% |
| 净利润同比 | -35.7% | -892.9% |
| 每股收益（稀释后） | $0.51 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHASIX
| Q4 25 | $183.1M | $359.9M | ||
| Q3 25 | $191.8M | $374.5M | ||
| Q2 25 | $174.4M | $410.0M | ||
| Q1 25 | $170.5M | $377.8M | ||
| Q4 24 | $186.5M | $329.1M | ||
| Q3 24 | $191.2M | $398.2M | ||
| Q2 24 | $182.4M | $453.5M | ||
| Q1 24 | $171.8M | $336.8M |
净利润AMPHASIX
| Q4 25 | $24.4M | $-2.8M | ||
| Q3 25 | $17.4M | $-2.6M | ||
| Q2 25 | $31.0M | $31.4M | ||
| Q1 25 | $25.3M | $23.3M | ||
| Q4 24 | $38.0M | $352.0K | ||
| Q3 24 | $40.4M | $22.3M | ||
| Q2 24 | $37.9M | $38.9M | ||
| Q1 24 | $43.2M | $-17.4M |
毛利率AMPHASIX
| Q4 25 | 46.8% | 7.6% | ||
| Q3 25 | 51.4% | 6.8% | ||
| Q2 25 | 49.6% | 14.3% | ||
| Q1 25 | 50.0% | 14.2% | ||
| Q4 24 | 46.5% | 3.4% | ||
| Q3 24 | 53.3% | 14.4% | ||
| Q2 24 | 52.2% | 17.9% | ||
| Q1 24 | 52.4% | 0.9% |
营业利润率AMPHASIX
| Q4 25 | 19.4% | -0.7% | ||
| Q3 25 | 13.2% | -0.9% | ||
| Q2 25 | 24.2% | 7.7% | ||
| Q1 25 | 21.9% | 7.7% | ||
| Q4 24 | 24.2% | -3.9% | ||
| Q3 24 | 29.8% | 7.5% | ||
| Q2 24 | 30.3% | 11.5% | ||
| Q1 24 | 27.9% | -7.0% |
净利率AMPHASIX
| Q4 25 | 13.3% | -0.8% | ||
| Q3 25 | 9.0% | -0.7% | ||
| Q2 25 | 17.8% | 7.7% | ||
| Q1 25 | 14.8% | 6.2% | ||
| Q4 24 | 20.4% | 0.1% | ||
| Q3 24 | 21.1% | 5.6% | ||
| Q2 24 | 20.8% | 8.6% | ||
| Q1 24 | 25.1% | -5.2% |
每股收益（稀释后）AMPHASIX
| Q4 25 | $0.51 | $-0.11 | ||
| Q3 25 | $0.37 | $-0.10 | ||
| Q2 25 | $0.64 | $1.15 | ||
| Q1 25 | $0.51 | $0.86 | ||
| Q4 24 | $0.74 | $0.02 | ||
| Q3 24 | $0.78 | $0.82 | ||
| Q2 24 | $0.73 | $1.43 | ||
| Q1 24 | $0.81 | $-0.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $19.8M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $815.2M |
| 总资产 | $1.6B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHASIX
| Q4 25 | $282.8M | $19.8M | ||
| Q3 25 | $276.2M | $23.7M | ||
| Q2 25 | $231.8M | $18.4M | ||
| Q1 25 | $236.9M | $8.3M | ||
| Q4 24 | $221.6M | $19.6M | ||
| Q3 24 | $250.5M | $17.3M | ||
| Q2 24 | $217.8M | $12.1M | ||
| Q1 24 | $289.6M | $20.6M |
总债务AMPHASIX
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHASIX
| Q4 25 | $788.8M | $815.2M | ||
| Q3 25 | $776.7M | $818.2M | ||
| Q2 25 | $757.5M | $823.7M | ||
| Q1 25 | $751.3M | $794.4M | ||
| Q4 24 | $732.3M | $774.6M | ||
| Q3 24 | $727.7M | $766.4M | ||
| Q2 24 | $713.3M | $746.6M | ||
| Q1 24 | $672.4M | $713.2M |
总资产AMPHASIX
| Q4 25 | $1.6B | $1.7B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.6B | $1.6B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.6B | $1.5B |
负债/权益比AMPHASIX
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $63.7M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $36.1M |
| 自由现金流率自由现金流/营收 | 13.4% | 10.0% |
| 资本支出强度资本支出/营收 | 4.5% | 7.7% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $6.4M |
8季度趋势，按日历期对齐
经营现金流AMPHASIX
| Q4 25 | $32.9M | $63.7M | ||
| Q3 25 | $52.6M | $26.6M | ||
| Q2 25 | $35.6M | $21.1M | ||
| Q1 25 | $35.1M | $11.4M | ||
| Q4 24 | $29.0M | $64.2M | ||
| Q3 24 | $60.0M | $57.3M | ||
| Q2 24 | $69.1M | $50.2M | ||
| Q1 24 | $55.3M | $-36.2M |
自由现金流AMPHASIX
| Q4 25 | $24.6M | $36.1M | ||
| Q3 25 | $47.2M | $66.0K | ||
| Q2 25 | $25.0M | $-7.2M | ||
| Q1 25 | $24.4M | $-22.6M | ||
| Q4 24 | $16.6M | $29.8M | ||
| Q3 24 | $46.2M | $26.8M | ||
| Q2 24 | $63.1M | $16.7M | ||
| Q1 24 | $46.5M | $-71.6M |
自由现金流率AMPHASIX
| Q4 25 | 13.4% | 10.0% | ||
| Q3 25 | 24.6% | 0.0% | ||
| Q2 25 | 14.3% | -1.7% | ||
| Q1 25 | 14.3% | -6.0% | ||
| Q4 24 | 8.9% | 9.1% | ||
| Q3 24 | 24.1% | 6.7% | ||
| Q2 24 | 34.6% | 3.7% | ||
| Q1 24 | 27.1% | -21.3% |
资本支出强度AMPHASIX
| Q4 25 | 4.5% | 7.7% | ||
| Q3 25 | 2.8% | 7.1% | ||
| Q2 25 | 6.1% | 6.9% | ||
| Q1 25 | 6.3% | 9.0% | ||
| Q4 24 | 6.7% | 10.4% | ||
| Q3 24 | 7.2% | 7.7% | ||
| Q2 24 | 3.3% | 7.4% | ||
| Q1 24 | 5.1% | 10.5% |
现金转化率AMPHASIX
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 0.67× | ||
| Q1 25 | 1.39× | 0.49× | ||
| Q4 24 | 0.76× | 182.29× | ||
| Q3 24 | 1.48× | 2.57× | ||
| Q2 24 | 1.82× | 1.29× | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
